Study S001477

Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03707171
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 30
Start: 2018-10-01
Primary completion: 2019-02-01
Lead sponsor: Third Military Medical University
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Liraglutide; DRUG:placebo
Results posted: FALSE

Registered primary outcomes

Changes of cognitive function assessed by cognitive function scale after 12 weeks. [Baseline,4weeks,8weeks，12weeks(End of Trial)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006745	Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway. Li Q, Journal of the American Heart Association	2021	Other trial	PMID 34250817 DOI	cites ClinicalTrials.gov:NCT03707171; registry reference DERIVED:34250817